IP Verse

Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein Reduction

Patent No. EP3529360 (titled "Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein Reduction") was filed by Novartis on Oct 18, 2017. The application was issued on Apr 17, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GRAF VON STOSCH PATENTANWALTSGESELLSCHAFTJan 17, 2025LEPTHIEN
TEVA PHARMACEUTICALSJan 17, 2025VON KAUFFMANN
INTAS PHARMACEUTICALSJan 16, 2025BRAND MURRAY FULLER
POLPHARMAJan 15, 2025WICHMANN
SYNTHONJan 10, 2025REDDIE & GROSE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3529360

NOVARTIS
Application Number
EP17800976A
Filing Date
Oct 18, 2017
Status
Granted And Under Opposition
Mar 15, 2024
Publication Date
Apr 17, 2024
External Links
Slate, Register , Google Patents